HI-Bio’s $95 Million Series B Financing Round

Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Voyager Therapeutics’ Capsid License Agreement and Strategic Collaboration with Novartis

Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction.  Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here